NCT04581135 is a clinical trial of COVID-19 in COVID-19, sponsored by Insel Gruppe AG, University Hospital Bern.

Who is sponsoring NCT04581135?

NCT04581135 is sponsored by Insel Gruppe AG, University Hospital Bern.

What drugs are being tested in NCT04581135?

Interventions in NCT04581135: COVID-19.

Is NCT04581135 still recruiting?

NCT04581135 is currently completed. Last updated 14 March 2023.

Last reviewed 2023-03-14 · How we verify

NCT04581135

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19

Completed Last updated 14 March 2023

What this trial tests

trial testing COVID-19 in COVID-19 in 620 participants. Completed in 30 January 2022.

Timeline

1 May 2020

Primary endpoint
30 January 2022

30 January 2022

Quick facts

Lead sponsor	Insel Gruppe AG, University Hospital Bern
Status	Completed
Study type	OBSERVATIONAL
Enrollment	620
Start date	1 May 2020
Primary completion	30 January 2022
Estimated completion	30 January 2022
Sites	9 locations across Switzerland

Drugs / interventions tested

COVID-19 — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Insel Gruppe AG, University Hospital Bern

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential.
Hussain I, Cher GLY, Abid MA, Abid MB. · · 2021 · cited 53× · PMID 34721437 · DOI 10.3389/fimmu.2021.765965
Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID.
Funke-Chambour M, Bridevaux PO, Clarenbach CF, Soccal PM, et al · · 2021 · cited 40× · PMID 34091456 · DOI 10.1159/000517255
Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study.
Lenoir A, Christe A, Ebner L, Beigelman-Aubry C, et al · · 2023 · cited 19× · PMID 36566741 · DOI 10.1159/000528611
Circulating calprotectin levels four months after severe and non-severe COVID-19.
Abu Hussein N, Machahua C, Ruchti SC, Horn MP, et al · · 2023 · cited 2× · PMID 37789266 · DOI 10.1186/s12879-023-08653-7

Verify or expand the search:

Other trials of COVID-19

Trials testing the same drug.

NCT07188116 — Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer · not yet recruiting
NCT05429047 — Priming of the NEonatal Immune System by Transfer of Maternal Immunity · unknown
NCT05481216 — HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV · completed
NCT05252442 — Association of the Risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID-19 Vaccines · completed
NCT05222750 — Epidemiology of Thrombotic Thrombocytopenia Syndrome in Integrated Health-care Database in England · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Insel Gruppe AG, University Hospital Bern trials

Trials by the same sponsor.

NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04581135 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
Last refreshed: 14 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04581135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing